Clinical trial
Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and…
NCT00151242 · University of Ulm, Other · Completed
Key facts
| NCT number | NCT00151242 |
|---|---|
| Title | Study on All-Trans Retinoic Acid, Induction and Consolidation Therapy, and Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Official title | Randomized Phase II/III-Study on All-Trans Retinoic Acid in Combination With Induction and Consolidation Therapy as Well as Pegfilgrastim After Consolidation Therapy in Younger Patients With Newly Diagnosed Acute Myeloid Leukemia |
| Lead sponsor | University of Ulm, Other |
| Status | Completed |
| Phase | Phase 2/Phase 3 |
| Study type | Interventional |
| Conditions | Acute Myeloid Leukemia |
| Intervention type | Drug |
| Interventions | Cytarabine, Idarubicin, Etoposide, All-trans retinoic acid, Pegfilgrastim |
| Enrollment | 920 |
| Start date | Jul 1, 2004 |
| Primary completion | Aug 1, 2011 |
| Completion | Aug 1, 2013 |
| First posted | Sep 8, 2005 |
| Last update posted | Sep 20, 2017 |
| Countries | Austria, Germany |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: